Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Are COX-2 selective inhibitors safer than NSAIDs for patients with osteoarthritis and rheumatoid arthritis?

Nature Clinical Practice Gastroenterology & Hepatology volume 4, pages 648–649 (2007)Cite this article

boxed-textLaine L et al. (2007) Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 369: 465–473

Patients with osteoarthritis or rheumatoid arthritis who are receiving either COX-2 selective inhibitors or NSAIDs combined with low-dose aspirin might need additional PPI therapy to decrease their risk of experiencing serious upper gastrointestinal complications

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Dubois RW et al. (2004) Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy. Aliment Pharmacol Ther 19: 197–208

    Article  CAS  Google Scholar 

  2. Lanas A and Hunt R (2006) Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategies. Ann Med 38: 415–428

    Article  CAS  Google Scholar 

  3. Rostom A et al. (2007) Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol 5: 818–828.e5

    Article  Google Scholar 

  4. Chan FK et al. (2002) Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 347: 2104–2110

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Rachel Jones, Associate Editor, Nature Clinical Practice.

Author information

Author notes

  1. Servicio de Aparato Digestivo, Hospital Clínico Universitario, Lozano Blesa, 50009 Zaragoza, Spain alanas@unizar.es

Authors and Affiliations

  1. A Lanas is Clinical Chief of Gastroenterology and a Professor of Medicine in the Department of Gastroenterology, University Hospital, Institute of Health Sciences of Aragon, Zaragoza, Spain.,

    Angel Lanas

Authors
  1. Angel Lanas
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declared associations with the following companies: AstraZeneca, Pfizer, Merck and Takeda. Angel Lanas is member of the Steering Committee for the APROVe Trial (Merck), and the GI Adjudication Committee for the CONDOR trial (Pfizer). He has also been a member of Advisory Boards for AstraZeneca and Pfizer, has received research funding from Pfizer, and honoraria for participating in different symposiums organized by AstraZeneca, Pfizer, Merck and Takeda.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lanas, A. Are COX-2 selective inhibitors safer than NSAIDs for patients with osteoarthritis and rheumatoid arthritis?. Nat Rev Gastroenterol Hepatol 4, 648–649 (2007). https://doi.org/10.1038/ncpgasthep0963

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpgasthep0963

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing